The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis
- PMID: 24070541
- DOI: 10.1164/rccm.201304-0760OC
The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis
Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a fatal progressive interstitial pneumonia. The innate immune system provides a crucial function in the recognition of tissue injury and infection. Toll-like receptor 3 (TLR3) is an innate immune system receptor. We investigated the role of a functional TLR3 single-nucleotide polymorphism in IPF.
Objectives: To characterize the effects of the TLR3 Leu412Phe polymorphism in primary pulmonary fibroblasts from patients with IPF and disease progression in two independent IPF patient cohorts. To investigate the role of TLR3 in a murine model of pulmonary fibrosis.
Methods: TLR3-mediated cytokine, type 1 IFN, and fibroproliferative responses were examined in TLR3 wild-type (Leu/Leu), heterozygote (Leu/Phe), and homozygote (Phe/Phe) primary IPF pulmonary fibroblasts by ELISA, real-time polymerase chain reaction, and proliferation assays. A murine model of bleomycin-induced pulmonary fibrosis was used in TLR3 wild-type (tlr3(+/+)) and TLR3 knockout mice (tlr3(-/-)). A genotyping approach was used to investigate the role of the TLR3 L412F polymorphism in disease progression in IPF using survival analysis and longitudinal decline in FVC.
Measurements and main results: Activation of TLR3 in primary lung fibroblasts from TLR3 L412F-variant patients with IPF resulted in defective cytokine, type I IFN, and fibroproliferative responses. We demonstrate increased collagen and profibrotic cytokines in TLR3 knockout mice (tlr3(-/-)) compared with wild-type mice (tlr3(+/+)). TLR3 L412F was also associated with a significantly greater risk of mortality and an accelerated decline in FVC in patients with IPF.
Conclusions: This study reveals the crucial role of defective TLR3 function in promoting progressive IPF.
Comment in
-
Idiopathic pulmonary fibrosis: time to get personal?Am J Respir Crit Care Med. 2013 Dec 15;188(12):1392-4. doi: 10.1164/rccm.201311-1956ED. Am J Respir Crit Care Med. 2013. PMID: 24328772 Free PMC article. No abstract available.
Similar articles
-
Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2022 Mar 1;205(5):550-562. doi: 10.1164/rccm.202010-3880OC. Am J Respir Crit Care Med. 2022. PMID: 34985402
-
Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis.QJM. 2018 Apr 1;111(4):217-224. doi: 10.1093/qjmed/hcx243. QJM. 2018. PMID: 29237089 Free PMC article.
-
Association of TLR3 L412F Polymorphism with Cytomegalovirus Infection in Children.PLoS One. 2017 Jan 3;12(1):e0169420. doi: 10.1371/journal.pone.0169420. eCollection 2017. PLoS One. 2017. PMID: 28046022 Free PMC article.
-
Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis.Expert Opin Ther Targets. 2015 Apr;19(4):507-14. doi: 10.1517/14728222.2014.988706. Epub 2014 Dec 22. Expert Opin Ther Targets. 2015. PMID: 25530171 Review.
-
Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis.Mil Med Res. 2022 May 12;9(1):21. doi: 10.1186/s40779-022-00382-3. Mil Med Res. 2022. PMID: 35550651 Free PMC article. Review.
Cited by
-
Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?Front Pharmacol. 2024 Aug 30;15:1445923. doi: 10.3389/fphar.2024.1445923. eCollection 2024. Front Pharmacol. 2024. PMID: 39281278 Free PMC article. Review.
-
Immune mechanisms in fibrotic interstitial lung disease.Cell. 2024 Jul 11;187(14):3506-3530. doi: 10.1016/j.cell.2024.05.015. Cell. 2024. PMID: 38996486 Review.
-
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.Am J Respir Crit Care Med. 2024 Aug 15;210(4):401-423. doi: 10.1164/rccm.202401-0238SO. Am J Respir Crit Care Med. 2024. PMID: 38573068 Review.
-
Genetic Underpinnings of Pulmonary Fibrosis: An Overview.Cardiovasc Hematol Agents Med Chem. 2024;22(3):367-374. doi: 10.2174/0118715257261006231207113809. Cardiovasc Hematol Agents Med Chem. 2024. PMID: 38284708 Review.
-
Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis.J Clin Med. 2023 Dec 31;13(1):241. doi: 10.3390/jcm13010241. J Clin Med. 2023. PMID: 38202248 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources